Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Atomo Diagnostics Ltd. ( (AU:AT1) ) just unveiled an announcement.
Atomo Diagnostics Limited has secured a material purchase order worth $502,000 to supply its HIV self-test kits, manufactured under the Mylan brand, to an African country with funding from the Global Fund, with delivery planned for March. The deal underscores ongoing demand for Atomo’s HIV self-testing solutions in African markets and reinforces the company’s role in providing reliable, discreet diagnostic options in regions with significant HIV risk, supporting both its revenue base and its positioning in global rapid diagnostics.
The most recent analyst rating on (AU:AT1) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Atomo Diagnostics Ltd. stock, see the AU:AT1 Stock Forecast page.
More about Atomo Diagnostics Ltd.
Atomo Diagnostics Limited is an Australian-headquartered medical device company that supplies patented, integrated rapid diagnostic test devices to the global diagnostics market. Its products are designed to simplify testing procedures, enhance usability and improve reliability in rapid point-of-care and at-home settings, with commercialised solutions and supply agreements covering applications such as HIV testing, viral versus bacterial differentiation and early pregnancy detection.
Average Trading Volume: 1,092,729
Technical Sentiment Signal: Buy
Current Market Cap: A$28.36M
See more insights into AT1 stock on TipRanks’ Stock Analysis page.